Notice of Annual General Meeting/Proxy Form
Released
Released
Announcement PDF
IMPACT MINERALS LIMITED
ACN 119 062 261
Notice of Annual General Meeting
The Annual General Meeting of the Company will be held as follows:
Time and date:
11.00am (WST) on Thursday, 30 November 2023
In Person:
Hall Chadwick WA Audit Pty Ltd, 283 Rokeby Road, Subiaco
Western Australia, 6008
The Notice of Annual General Meeting should be read in its entirety. If Shareholders are in
doubt as to how to vote, they should seek advice from a suitably qualified professional
advisor prior to voting.
Should you wish to discuss any matter, please do not hesitate to contact the
Company Secretary by telephone on (08) 6454 6666.
Shareholders are urged to vote by lodging the Proxy Form
Page 1
IMPACT MINERALS LIMITED
ACN 119 062 261
(Company)
Notice of Annual General Meeting
Notice is hereby given that the annual general meeting of Shareholders of Impact Minerals Limited
(ACN 119 062 261) will be held at Hall Chadwick WA Audit Pty Ltd, 283 Rokeby Road, Subiaco,
Western Australia, 6008 at 11.00am (WST) on Thursday, 30 November 2023 (Meeting).
The Explanatory Memorandum provides additional information on matters to be considered at the
Meeting. The Explanatory Memorandum and the Proxy Form form part of the Notice.
Terms and abbreviations used in the Notice are defined in Schedule 1.
Agenda
1
Annual Report
To consider the Annual Report of the Company and its controlled entities for the financial year
ended 30 June 2023, which includes the Financial Report, the Directors' Report and the
Auditor's Report.
Note: there is no requirement for Shareholders to approve the Annual Report.
2
Resolutions
Resolution 1 – Remuneration Report
To consider and, if thought fit, to pass with or without amendment, as a non-binding ordinary
resolution the following:
'That the Remuneration Report be adopted by Shareholders on the terms and conditions in
the Explanatory Memorandum.'
Note: a vote on this Resolution is advisory only and does not bind the Directors or the
Company.
Resolution 2 – Re-election of Director – Dr Frank Bierlein
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
'That Dr Frank Bierlein, who retires by rotation in accordance with Article 7.2 of the
Constitution, Listing Rule 14.5 and for all other purposes, and, being eligible and offering
himself for re-election, is re-elected as a Director on the terms and conditions in the
Explanatory Memorandum.'
Page 2
Resolution 3 – Approval of 10% Placement Facility
To consider and, if thought fit, to pass with or without amendment, as a special resolution the
following:
‘That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes,
Shareholders approve the issue of Equity Securities totalling up to 10% of the issued capital of
the Company at the time of issue, calculated in accordance with the formula prescribed in
Listing Rule 7.1A.2 and on the terms and conditions in the Explanatory Memorandum.'
Resolution 4 – Approval of Issue of Performance Rights to Director –
Dr Mike Jones
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
‘That, pursuant to and in accordance with Listing Rule 10.14, sections 195(4) and 208 of the
Corporations Act and for all other purposes, Shareholders approve the issue of 60,000,000
Performance Rights to Dr Mike Jones (or his nominee), on the terms and conditions in the
Explanatory Memorandum.’
Resolution 5 – Approval of Issue of Performance Rights to Director –
Mr Peter Unsworth
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
‘That, pursuant to and in accordance with Listing Rule 10.14, sections 195(4) and 208 of the
Corporations Act and for all other purposes, Shareholders approve the issue of 30,000,000
Performance Rights to Mr Peter Unsworth (or his nominee), on the terms and conditions in the
Explanatory Memorandum.’
Resolution 6 – Approval of Issue of Performance Rights to Director –
Mr Paul Ingram
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
‘That, pursuant to and in accordance with Listing Rule 10.14, sections 195(4) and 208 of the
Corporations Act and for all other purposes, Shareholders approve the issue of 12,000,000
Performance Rights to Mr Paul Ingram (or his nominee), on the terms and conditions in the
Explanatory Memorandum.’
Page 3
Resolution 7 – Approval of Issue of Performance Rights to Director –
Dr Frank Bierlein
To consider and, if thought fit, to pass with or without amendment, as an ordinary resolution
the following:
‘That, pursuant to and in accordance with Listing Rule 10.14, sections 195(4) and 208 of the
Corporations Act and for all other purposes, Shareholders approve the issue of 8,000,000
Performance Rights to Dr Frank Bierlein (or his nominee), on the terms and conditions in the
Explanatory Memorandum.’
Voting exclusions
Pursuant to the Listing Rules, the Company will disregard any votes cast in favour of:
(a)
Resolution 3, if at the time of the Meeting, the Company is proposing to make an issue
of Equity Securities under Listing Rule 7.1A.2, by or on behalf of any persons who are
expected to participate in, or who will obtain a material benefit as a result of, the
proposed issue (except a benefit solely by reason of being a Shareholder), or any of
their respective associates;
(b)
Resolution 4 by or on behalf of Dr Mike Jones or any person referred to in Listing Rule
10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the Plan, or any of their
respective associates;
(c)
Resolution 5 by or on behalf of Mr Peter Unsworth or any person referred to in Listing
Rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the Plan, or any of
their respective associates;
(d)
Resolution 6 by or on behalf of Mr Paul Ingram or any person referred to in Listing
Rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the Plan), or any of
their respective associates; and
(e)
Resolution 7 by or on behalf of Dr Frank Bierlein or any person referred to in Listing
Rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the Plan, or any of
their respective associates.
The above voting exclusions do not apply to a vote cast in favour of the relevant Resolution
by:
(a)
a person as proxy or attorney for a person who is entitled to vote, in accordance with
directions given to the proxy or attorney to vote on the Resolution in that way; or
(b)
the Chair as proxy or attorney for a person who is entitled to vote, in accordance with
a direction given to the Chair to vote on the Resolution as the Chair decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on
behalf of a beneficiary provided the following conditions are met:
(i)
the beneficiary provides written confirmation to the holder that the beneficiary
is not excluded from voting, and is not an associate of a person excluded from
voting, on the Resolution; and
Page 4
(ii)
the holder votes on the Resolution in accordance with directions given by the
beneficiary to the holder to vote in that way.
Voting prohibitions
Resolution 1: In accordance with sections 250BD and 250R of the Corporations Act, a vote
on this Resolution must not be cast (in any capacity) by or on behalf of a member of the Key
Management Personnel details of whose remuneration are included in the Remuneration
Report, or a Closely Related Party of such a member.
A vote may be cast by such person if the vote is not cast on behalf of a person who is
excluded from voting on this Resolution, and:
(a)
the person is appointed as a proxy by writing that specifies the way the proxy is to
vote on this Resolution; or
(b)
the voter is the Chair and the appointment of the Chair as proxy does not specify the
way the proxy is to vote on this Resolution, but expressly authorises the Chair to
exercise the proxy even if this Resolution is connected with the remuneration of a
member of the Key Management Personnel.
Resolution 4, Resolution 5, Resolution 6 and Resolution 7: In accordance with
section 250BD of the Corporations Act, a person appointed as a proxy must not vote, on the
basis of that appointment, on this Resolution if:
(a)
the proxy is either a member of the Key Management Personnel or a Closely Related
Party of such member; and
(b)
the appointment does not specify the way the proxy is to vote on this Resolution.
However, the above prohibition does not apply if:
(a)
the proxy is the Chair; and
(b)
the appointment expressly authorises the Chair to exercise the proxy even though this
Resolution is connected directly or indirectly with remuneration of a member of the
Key Management Personnel.
Further, in accordance with section 224 of the Corporations Act, a vote on this Resolution
must not be cast (in any capacity) by or on behalf of a related party of the Company to whom
the Resolution would permit a financial benefit to be given, or an associate of such a related
party.
However, the above prohibition does not apply if:
(a)
it is cast by a person as a proxy appointed by writing that specifies how the proxy is to
vote on the Resolution; and
(b)
it is not cast on behalf of a related party of the Company to whom the Resolution
would permit a financial benefit to be given, or an associate of such a related party.
Please note: If the Chair is a person referred to in the section 224 Corporations Act voting
prohibition statement above, the Chair will only be able to cast a vote as proxy for a person
Page 5
who is entitled to vote if the Chair is appointed as proxy in writing and the Proxy Form
specifies how the proxy is to vote on the relevant Resolution.
If you purport to cast a vote other than as permitted above, that vote will be disregarded by the
Company (as indicated above) and you may be liable for breaching the voting restrictions that
apply to you under the Corporations Act.
BY ORDER OF THE BOARD
Bernard Crawford
Company Secretary
Impact Minerals Limited
Dated: 20 October 2023
Page 6
IMPACT MINERALS LIMITED
ACN 119 062 261
(Company)
Explanatory Memorandum
1.
Introduction
The Explanatory Memorandum has been prepared for the information of Shareholders in
connection with the business to be conducted at the Meeting to be held at Hall Chadwick WA
Audit Pty Ltd, 283 Rokeby Road, Subiaco, Western Australia 6008 on Thursday, 30 November
2023 at 11.00am (WST).
The Explanatory Memorandum forms part of the Notice which should be read in its entirety.
The Explanatory Memorandum contains the terms and conditions on which the Resolutions
will be voted.
The Explanatory Memorandum includes information about the following to assist Shareholders
in deciding how to vote on the Resolutions:
Section 2
Action to be taken by Shareholders
Section 3
Annual Report
Section 4
Resolution 1 – Remuneration Report
Section 5
Resolution 2 – Re-election of Director – Dr Frank Bierlein
Section 6
Resolution 3 – Approval of 10% Placement Facility
Section 7
Resolution 4 to Resolution 7 – Approval of Issue of Performance
Rights to Directors
Schedule 1
Definitions
Schedule 2
Summary of Employee Securities Incentive Plan
A Proxy Form is located at the end of the Explanatory Memorandum.
2.
Action to be taken by Shareholders
Shareholders should read the Notice including the Explanatory Memorandum carefully before
deciding how to vote on the Resolutions.
2.1
Voting in person
To vote in person, attend the Meeting on the date and at the place set out above.
Page 7
2.2
Voting by proxy
A Proxy Form is attached to the Notice. This is to be used by Shareholders if they wish to
appoint a representative (a ‘proxy’) to vote in their place. All Shareholders are invited and
encouraged to attend the Meeting or, if they are unable to attend in person, sign and return the
Proxy Form to the Company in accordance with the instructions thereon, which must be
submitted no later than 11.00am (WST) on Tuesday, 28 November 2023. Lodgement of a
Proxy Form will not preclude a Shareholder from attending and voting at the Meeting in
person.
Please note that:
(a)
a member of the Company entitled to attend and vote at the Meeting is entitled to
appoint a proxy;
(b)
a proxy need not be a member of the Company; and
(c)
a member of the Company entitled to cast two or more votes may appoint two proxies
and may specify the proportion or number of votes each proxy is appointed to
exercise, but where the proportion or number is not specified, each proxy may
exercise half of the votes.
The enclosed Proxy Form provides further details on appointing proxies and lodging Proxy
Forms.
Section 250BB(1) of the Corporations Act provides that an appointment of a proxy may specify
the way the proxy is to vote on a particular resolution and, if it does:
(a)
the proxy need not vote on a show of hands, but if the proxy does so, the proxy must
vote that way (i.e. as directed);
(b)
if the proxy has 2 or more appointments that specify different ways to vote on the
resolution – the proxy must not vote on a show of hands;
(c)
if the proxy is the Chair of the meeting at which the resolution is voted on – the proxy
must vote on a poll, and must vote that way (i.e. as directed); and
(d)
if the proxy is not the Chair – the proxy need not vote on the poll, but if the proxy does
so, the proxy must vote that way (i.e. as directed).
(e)
Section 250BC of the Corporations Act provides that, if:
(i)
an appointment of a proxy specifies the way the proxy is to vote on a
particular resolution at a meeting of the Company’s members;
(ii)
the appointed proxy is not the Chair of the meeting;
(iii)
at the meeting, a poll is duly demanded, or is otherwise required under section
250JA on the resolution; and
(iv)
either the proxy is not recorded as attending the meeting or the proxy does not
vote on the resolution,
the Chair of the meeting is taken, before voting on the resolution closes, to have been
appointed as the proxy for the purposes of voting on the resolution at the meeting.
Page 8
2.3
Voting eligibility
The Directors have determined that pursuant to Regulation 7.11.37 of the Corporations
Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those persons who
are registered Shareholders at 4.00pm (WST) on Tuesday, 28 November 2023.
2.4
Chair's voting intentions
If the Chair is your proxy, either by appointment or by default, and you have not indicated your
voting intention, you expressly authorise the Chair to exercise the proxy in respect of
Resolution 1 and Resolution 4 to Resolution 7 (inclusive), even though these Resolutions are
connected directly or indirectly with the remuneration of the Company’s Key Management
Personnel.
Subject to the following paragraph, the Chair intends to exercise all available proxies in favour
of all Resolutions, unless the Shareholder has expressly indicated a different voting intention.
If the Chair is a person referred to in the voting prohibition statement applicable to a
Resolution (under section 224 of the Corporations Act), the Chair will only be able to cast a
vote as proxy for you on the relevant Resolution if you are entitled to vote and have specified
your voting intention in the Proxy Form.
2.5
Submitting Questions
Shareholders may submit questions in advance of the Meeting to the Company. Questions
must be submitted by emailing the Company Secretary at bernardc@impactminerals.com.au
by 4.00pm (WST) on Tuesday, 28 November 2023.
Shareholders will also have the opportunity to submit questions during the Meeting in respect
to the formal items of business. In order to ask a question during the Meeting, please follow
the instructions from the Chair.
The Chair will attempt to respond to the questions during the Meeting. The Chair will request
prior to a Shareholder asking a question that they identify themselves (including the entity
name of their shareholding and the number of Shares they hold).
3.
Annual Report
In accordance with section 317 of the Corporations Act, Shareholders will be offered the
opportunity to discuss the Annual Report, including the Financial Report, the Directors' Report
and the Auditor's Report for the financial year ended 30 June 2023.
There is no requirement for Shareholders to approve the Annual Report.
At the Meeting, Shareholders will be offered the opportunity to:
(a)
discuss the Annual Report which is available online at
https://www.impactminerals.com.au/site/investor-centre/annual-reports;
(b)
ask questions about, or comment on, the management of the Company; and
(c)
ask the auditor questions about the conduct of the audit and the preparation and
content of the Auditor's Report.
Page 9
In addition to taking questions at the Meeting, written questions to the Chair about the
management of the Company, or to the Company's auditor about:
(a)
the preparation and content of the Auditor's Report;
(b)
the conduct of the audit;
(c)
accounting policies adopted by the Company in relation to the preparation of the
financial statements; and
(d)
the independence of the auditor in relation to the conduct of the audit,
may be submitted no later than five business days before the Meeting to the Company
Secretary at the Company's registered office.
The Company will not provide a hard copy of the Company's Annual Report to Shareholders
unless specifically requested to do so.
4.
Resolution 1 – Remuneration Report
4.1
General
In accordance with subsection 250R(2) of the Corporations Act, the Company must put the
Remuneration Report to the vote of Shareholders. The Directors' Report for the year ended
30 June 2023 in the 2023 Annual Report contains the Remuneration Report which sets out the
remuneration policy for the Company and the remuneration arrangements in place for the
executive Directors, specified executives and non-executive Directors.
In accordance with subsection 250R(3) of the Corporations Act, Resolution 1 is advisory only
and does not bind the Directors. If Resolution 1 is not passed, the Directors will not be
required to alter any of the arrangements in the Remuneration Report.
If the Company's Remuneration Report receives a 'no' vote of 25% or more (Strike) at two
consecutive annual general meetings, Shareholders will have the opportunity to remove the
whole Board, except the managing director (if any).
Where a resolution on the Remuneration Report receives a Strike at two consecutive annual
general meetings, the Company will be required to put to Shareholders at the second annual
general meeting a resolution on whether another meeting should be held (within 90 days) at
which all Directors (other than the managing director, if any) who were in office at the date of
approval of the applicable Directors' Report must stand for re-election.
The Company's Remuneration Report did not receive a Strike at the 2022 annual general
meeting held on 24 November 2022. If the Remuneration Report receives a Strike at this
Meeting, Shareholders should be aware that if a second Strike is received at the 2024 annual
general meeting, this may result in the re-election of the Board.
The Chair will allow a reasonable opportunity for Shareholders as a whole to ask about, or
make comments on the Remuneration Report.
Page 10
4.2
Additional information
Resolution 1 is an ordinary resolution.
Given the material personal interests of all Directors in this Resolution, the Board makes no
recommendation to Shareholders regarding this Resolution.
5.
Resolution 2 – Re-election of Director – Dr Frank Bierlein
5.1
General
Article 7.2 of the Constitution and Listing Rule 14.5 both provide that there must be an election
of Directors at each annual general meeting of the Company. If no person or Director is
standing for election or re-election in accordance with other Articles of the Constitution,
Article 7.2(b)(iv) provides that that any director who wishes to may retire and stand for reelection.
Dr Frank Bierlein, Non-Executive Director, was last elected at the annual general meeting held
on 30 November 2021.
Accordingly, Dr Bierlein retires by rotation at this Meeting and, being eligible, seeks re-election
pursuant to Resolution 2.
If elected, Dr Bierlein is considered by the Board (with Dr Bierlein abstaining) to be an
independent Director, notwithstanding Dr Bierlein holds incentive Options and may be granted
Performance Rights if Resolution 7 is passed. Dr Bierlein is not considered by the Board to
hold any material interest, position or relationship that might influence, or reasonably be
perceived to influence, in a material respect his capacity to bring an independent judgement to
bear on issues before the Board and to act in the best interests of the entity as a whole rather
than in the interests of an individual security holder or other party.
Dr Bierlein has acknowledged to the Company that he will have sufficient time to fulfil his
responsibilities as a Director.
5.2
Dr Frank Bierlein
Dr Bierlein is a geologist with 30 years of experience as a consultant, researcher, lecturer and
industry professional. Dr Bierlein has held exploration and generative geology management
positions with QMSD Mining Co Ltd, Qatar Mining, Afmeco Australia and Areva NC, and
consulted for, among others, Newmont Gold, Resolute Mining, Goldfields International,
Freeport-McMoRan, and the International Atomic Energy Agency. He was a non-executive
director of Gold Australia Pty Ltd from 2015 to 2019 and chaired the Advisory Board of a
Luxemburg- based private equity fund between 2014 and 2021. Dr Bierlein has worked on six
continents spanning multiple commodities, and over the course of his career has published
and co-authored more than 130 articles in peer-reviewed scientific journals. Dr Bierlein
obtained a PhD (Geology) from the University of Melbourne, is a Fellow of the Australian
Institute of Geoscientists (AIG), and a member of both the Society of Economic Geologists
(SEG) and the Society of Geology Applied to Mineral Deposits.
Dr Bierlein does not currently hold any other material directorships, other than as disclosed in
this Notice.
The Company confirms that it took appropriate checks into Dr Bierlein’s background and
experience and that these checks did not identify any information of concern.
Page 11
5.3
Board recommendation
Resolution 2 is an ordinary resolution.
The Board (other than Dr Bierlein who has a personal interest in the outcome of this
Resolution) recommends that Shareholders vote in favour of Resolution 2 for the following
reasons:
(a)
Dr Bierlein has over 30 years' experience in exploration and generative geology
spanning six continents and has held management positions at a variety of reputable
organisations; and
(b)
Dr Bierlein's wide-ranging board experience across a number of public exploration and
mining companies will be invaluable to the Board during the next stage of the
Company’s development.
6.
Resolution 3 – Approval of 10% Placement Facility
6.1
General
Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of
Equity Securities that a listed company can issue without the approval of its shareholders over
any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of
that period.
Under Listing Rule 7.1A, however, an eligible entity can seek approval from its members, by
way of a special resolution passed at its annual general meeting, to increase this 15% limit by
an extra 10% to 25% (10% Placement Facility).
Resolution 3 seeks Shareholder approval by way of a special resolution to provide the
Company the ability to issue Equity Securities under the 10% Placement Facility during the
10% Placement Period (refer to Section 6.2(f) below). The number of Equity Securities to be
issued under the 10% Placement Facility will be determined in accordance with the formula
prescribed in Listing Rule 7.1A.2 (refer to Section 6.2(c) below).
If Resolution 3 is passed, and subject to the Company's temporary restriction on issuing
Equity Securities under Listing Rules 7.1 and 7.1A until 12 January 2024 (refer to Section
7.6(j) below), the Company will be able to issue Equity Securities up to the combined 25% limit
in Listing Rules 7.1 and 7.1A without any further shareholder approval.
If Resolution 3 is not passed, the Company will not be able to access the additional 10%
capacity to issue Equity Securities without Shareholder approval provided for in Listing
Rule 7.1A and will remain subject to the 15% limit on issuing Equity Securities without
Shareholder approval set out in Listing Rule 7.1 (again, subject to the temporary restriction
until 12 January 2024 discussed in Section 7.6(j) below).
6.2
Listing Rule 7.1A
(a)
Is the Company an eligible entity?
An 'eligible entity' means an entity which is not included in the S&P/ASX 300 Index
and which has a market capitalisation of $300 million or less.
Page 12
The Company is an eligible entity for these purposes as it is not included in the
S&P/ASX 300 Index and has a market capitalisation of approximately $28.7 million,
based on the closing price of Shares of $0.01 on 13 October 2023.
(b)
What Equity Securities can be issued?
Any Equity Securities issued under the 10% Placement Facility must be in the same
class as an existing quoted class of Equity Securities of the eligible entity.
As at the date of the Notice, the Company has on issue two quoted classes of Equity
Securities: Shares and Listed Options.
(c)
How many Equity Securities can be issued?
Listing Rule 7.1A.2 provides that under the approved 10% Placement Facility, the
Company may issue or agree to issue a number of Equity Securities calculated in
accordance with the following formula:
(A x D) – E
Where:
A=
the number of Shares on issue at the commencement of the Relevant Period:
(A)
plus the number of fully paid Shares issued in the Relevant Period
under an exception in Listing Rule 7.2 (other than exception 9, 16 or
17);
(B)
plus the number of fully paid Shares issued in the Relevant Period on
the conversion of convertible securities within Listing Rule 7.2
exception 9 where:
(C)
(1)
the convertible securities were issued or agreed to be issued
before the commencement of the Relevant Period; or
(2)
the issue of, or agreement to issue, the convertible securities
was approved, or taken under the Listing Rules to have been
approved, under Listing Rule 7.1 or 7.4;
plus the number of fully paid Shares issued in the Relevant Period
under an agreement to issue securities within Rule 7.2 exception 16
where:
(1)
the agreement was entered into before the commencement of
the Relevant Period; or
(2)
the agreement or issue was approved, or taken under the
Listing Rules to be approved, under Listing Rule 7.1 or 7.4.
(D)
plus the number of any other fully paid Shares issued in the Relevant
Period with approval under Listing Rule 7.1 or 7.4;
(E)
plus the number of partly paid shares that became fully paid in the
12 months; and
Page 13
(F)
less the number of fully paid Shares cancelled in the Relevant Period.
Note that 'A' has the same meaning in Listing Rule 7.1 when calculating the
Company's 15% annual placement capacity.
D
is 10%.
E
is the number of Equity Securities issued or agreed to be issued under Listing
Rule 7.1A.2 in the Relevant Period before the date of the issue or agreement
to issue that are not issued with Shareholder approval under Listing Rule 7.1
or 7.4; and
"relevant period" has the same meaning as in rule 7.1.
(d)
What is the interaction with Listing Rule 7.1?
The Company's ability to issue Equity Securities under Listing Rule 7.1A will be in
addition to its 15% annual placement capacity under Listing Rule 7.1.
(e)
At what price can the Equity Securities be issued?
Any Equity Securities issued under Listing Rule 7.1A must be issued for a cash
consideration per security which is not less than 75% of the VWAP of Equity
Securities in the same class calculated over the 15 Trading Days on which trades in
that class were recorded immediately before:
(i)
the date on which the price at which the Equity Securities are to be issued is
agreed by the Company and the recipient of the Equity Securities; or
(ii)
if the Equity Securities are not issued within 10 Trading Days of the date in
paragraph (i) above, the date on which the Equity Securities are issued,
(Minimum Issue Price).
(f)
When can Equity Securities be issued?
Shareholder approval of the 10% Placement Facility under Listing Rule 7.1A will,
subject to the Company's temporary restriction on issuing Equity Securities under
Listing Rules 7.1 and 7.1A until 12 January 2024 (refer to Section 7.6(j) below), be
valid from the date of Meeting and will expire on the earlier to occur of:
(i)
the date that is 12 months after the date of the Meeting;
(ii)
the time and date of the Company's next annual general meeting; or
(iii)
the date of Shareholder approval of a transaction under Listing Rules 11.1.2
(a significant change to the nature or scale of activities) or 11.2 (disposal of
main undertaking),
(10% Placement Period).
(g)
What is the effect of Resolution 3?
The effect of Resolution 3 will be to allow the Directors to issue the Equity Securities
under Listing Rule 7.1A during the 10% Placement Period without further Shareholder
Page 14
approval or using the Company's 15% annual placement capacity under Listing
Rule 7.1.
6.3
Specific information required by Listing Rule 7.3A
Under and for the purposes of Listing Rule 7.3A, the following information is provided in
relation to the 10% Placement Facility:
(a)
Final date for issue
The Company will only issue the Equity Securities under the 10% Placement Facility
during the 10% Placement Period (refer to Section 6.2(f) above).
Shareholder approval of the 10% Placement Facility will cease to b
Share your feedback
Discover